Leprosy, previously known as Hansen's disease, is a chronic infectious disease caused by Mycobacterium leprae and present mainly in tropical developing nations.
It is most common in tropical developing countries and is endemic in over 100 countries. Worldwide there is a prevalence of 3 per 100,000 people 4. A progressive decline in prevalence rates has been observed all around the world with multi-drug treatment 2-4.
There is a long incubation of ~3 years (range six months-20 years) between infection and onset of multi-systemic symptoms and signs 4,7:
- cutaneous erythematous plaques
- peripheral lower limb oedema
- mixed peripheral neuropathy (often with resultant injuries) +/- hypoesthesia/paresthesia +/- neuralgia
- peripheral nerve thickening, which may be palpable
Mycobacterium leprae attacks the skin and peripheral nerves and has a predilection for the cooler appendages of the body with characteristic involvement of the small bones of the hands and feet.
Bone lesions in patients with leprosy are usually due to trauma and secondary bacterial infection superimposed on denervated tissues.
Bone lesions due to direct leprous infection are unusual, varying from 3-5% in one series, and these lesions exhibit radiologic findings of acute and chronic osteomyelitis similar to those of other granulomatous infectious agents.
The radiologic findings are similar to those caused by other conditions in which sensory impairment is complicated by traumatic injury and infection (Charcot joint)
Motor denervation due to leprous infection of peripheral nerves contributes to deformities such as claw hand and claw toes and is sometimes associated with the development of concentric bone atrophy.
Absorption of bone in leprosy manifests as a decrease in bone length and width and results in a tapered appearance at the end of the bone, which has been likened to a licked candy stick.
When complicated by repeated microtrauma, secondary bacterial infection, or both, digits may be resorbed.
Treatment and prognosis
- multidrug therapy: dapsone, clofazimine and rifampicin
- monotherapy is no longer use; WHO recommends 6 and 12-month regimens for paucibacillary and multibacillary disease respectively 5
- prognosis: good in early and mild cases; advanced cases (marked loss of tissue and nerve deformity) are incurable 6
History and etymology
It was named after Gerhard Armauer Hansen, a Norwegian physician who identified the bacillus Mycobacterium leprae as the cause of the disease in 1873 3.
The differential for musculoskeletal changes is largely that of other causes of a Charcot joint and tissue loss, including:
- 1. Jones EA, Manaster BJ, May DA et-al. Neuropathic osteoarthropathy: diagnostic dilemmas and differential diagnosis. Radiographics. 2000;20 Spec No : S279-93. Radiographics (link) - Pubmed citation
- 2. Alves CR, Ribeiro MM, Melo EM et-al. Teaching of leprosy: current challenges. An Bras Dermatol. 2014;89 (3): 454-9. Free text at pubmed - Pubmed citation
- 3. Lastória JC, Abreu MA. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89 (2): 205-18. Free text at pubmed - Pubmed citation
- 4. Lastória JC, Abreu MA. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89 (2): 205-18. Free text at pubmed - Pubmed citation
- 5. Eichelmann K, González González SE, Salas-Alanis JC, Ocampo-Candiani J: Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr. 2013 Sep;104(7):554-63. doi: 10.1016/j.adengl.2012.03.028. Epub 2013 Jul 17. http://www.ncbi.nlm.nih.gov/pubmed/23870850
- 6. Harper P: The treatment and prognosis of leprosy, Br Med J. 1922 Jul 8; 2(3210): 39–40. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2416408/
- 7. Oxford textbook of medicine. Oxford University Press. ISBN:0192629220. Read it at Google Books - Find it at Amazon